Washington, D.C. – In an effort to help the Rhode Island state government improve service delivery to Medicaid patients and reduce bureaucracy, U.S. Senator Jack Reed (D-RI) and Sheldon Whitehouse (D-RI) today announced that the U.S. Department of Health and Human Services (HHS) will award the state of Rhode Island $725,253 to update and upgrade…
PRINCETON, NJ / ACCESSWIRE / December 15, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2022 and provided a business update. Pankaj Mohan, Ph.D., Founder and CEO commented, “This was a defining…
Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp up site activation in Asia and Nanobiotix adds European sites, and begins recruitment in the US Reported €63.0 million in cash and cash equivalents as of June 30, 2022 which,…
The last unofficial week of summer was relatively slow in the online travel world, though last week did see the release of the European Commission’s report on its recent study into the current status of hotel room distribution in the E.U. We’ve attached a short summary of the report as well as a link to…
Ocugen Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review Ocugen’s exclusive territory for COVAXIN™ (BBV152) marketing expanded to include all of North America MALVERN, Pa., May 06, 2022 (GLOBE NEWSWIRE)…